Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Current Leases (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Current Leases for 5 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For Q4 2025, Current Leases fell 34.03% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, down 34.03%, while the annual FY2025 figure was $2.3 million, 34.03% down from the prior year.
  • Current Leases hit $2.3 million in Q4 2025 for Kezar Life Sciences, down from $3.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.8 million in Q2 2025 and bottomed at $1.1 million in Q1 2021.
  • Average Current Leases over 5 years is $2.4 million, with a median of $2.7 million recorded in 2023.
  • Year-over-year, Current Leases surged 117.83% in 2023 and then plummeted 34.03% in 2025.
  • Kezar Life Sciences' Current Leases stood at $1.2 million in 2021, then soared by 113.93% to $2.6 million in 2022, then rose by 17.43% to $3.0 million in 2023, then grew by 17.07% to $3.5 million in 2024, then tumbled by 34.03% to $2.3 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.3 million, $3.3 million, and $3.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.